Cargando…

1378. Impact of Cytomegalovirus Prophylaxis on Clinical Outcomes in Kidney Transplantation: A United States Renal Data System-Medicare Linked Database Study

BACKGROUND: Guidelines recommends cytomegalovirus (CMV) prophylaxis by CMV serostatus/risk status, as the currently available antiviral agents may lead to myelosuppressive events in kidney transplant recipients (KTRs). Limited data exist for the United States (US) on the such clinical outcomes with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raval, Amit D, Ganz, Michael, Saravanan, Priya, Tang, Yuexin, Santos, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644690/ http://dx.doi.org/10.1093/ofid/ofab466.1570

Ejemplares similares

1387. Impact of Cytomegalovirus Prophylaxis on Healthcare Resource Use and Costs among Kidney Transplant Recipients: A United States Renal Data System-Medicare Linked Database Study
por: Raval, Amit D, et al.
Publicado: (2021)

Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
por: Raval, Amit D., et al.
Publicado: (2022)

Expression of Concern: Real-World Treatment Patterns of Antiviral Prophylaxis for Cytomegalovirus Among Adult Kidney Transplant Recipients: A Linked USRDS-Medicare Database Study
Publicado: (2023)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

1706. Association between Cytomegalovirus Infection/Disease and Morbidity and Mortality in Kidney Transplantation: A Systematic Literature Review of Observational Studies
por: Raval, Amit D, et al.
Publicado: (2020)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

210. Neutropenia and Associated Infectious Complications Among Kidney Transplant Recipients Receiving Valganciclovir Prophylaxis in the United States: An Administrative Claims Database Study
por: Turzhitsky, Vladimir, et al.
Publicado: (2022)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Cytomegalovirus in the transplanted kidney: a report of two cases and review of prophylaxis
por: Meyrier, A., et al.
Publicado: (2011)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients
por: Park, Woo Yeong, et al.
Publicado: (2020)

1378. Clinical Characteristics of Tuberculosis Among Patients with Cancer in an Endemic Country
por: Buppanharun, Jirawat, et al.
Publicado: (2019)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?
por: Madi, Nada, et al.
Publicado: (2011)

Molecular Detection and Genotyping of Human Cytomegalovirus in Kidney Transplant Recipients under Ganciclovir Prophylaxis in Iran
por: Behnezhad, Farzane, et al.
Publicado: (2022)

1378. Seroprevalence and risk factors for cysticercosis in Mexican-Americans in Starr County, Texas
por: Duffey, Megan M, et al.
Publicado: (2023)

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
por: Huang, Glen, et al.
Publicado: (2020)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Reforma al artículo 1378, párrafo II del código de comercio vigente
por: Huerta López, Luis
Publicado: (2013)

Clinical Characteristics of 1378 Inpatients with Spinal Tuberculosis in General Hospitals in South-Central China
por: Liu, Zheng, et al.
Publicado: (2019)

Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
por: Selvey, Linda A., et al.
Publicado: (2017)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

Cytomegalovirus infection after renal transplantation
por: Al Atbee, Mohammed Younus Naji, et al.
Publicado: (2022)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
por: Golan, Yoav, et al.
Publicado: (2021)

Prevalence of cytomegalovirus disease in kidney transplant patients in an intensive care unit
por: dos Santos, Sanmya Danielle Rodrigues, et al.
Publicado: (2017)

Holoendemic cytomegalovirus infection in renal transplant recipients.
por: Fiala, M., et al.
Publicado: (1976)

Ganciclovir-resistant cytomegalovirus infection in renal transplantation
por: Vaz, Raquel, et al.
Publicado: (2014)

2-Phenyl-1H-1,3,7,8-tetraazacyclopenta[l]phenanthrene
por: Xi, Hong-Min
Publicado: (2008)

2-Phenyl-1H-1,3,7,8-tetraazacyclopenta[l]phenanthrene
por: Liu, Dong-Ming, et al.
Publicado: (2009)

Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
por: Immohr, Moritz B., et al.
Publicado: (2021)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Geographic Distribution of Cytomegalovirus Serology in Kidney and Pancreas Transplant Recipients in the United States
por: Jorgenson, Margaret R., et al.
Publicado: (2021)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Mucormycosis and Cytomegalovirus Co-infection in Renal Transplant Recipients
por: Gupta, K. L.
Publicado: (2017)

Cytomegalovirus-Related Hemophagocytic Lymphohistiocytosis after Renal Transplantation
por: Anandh, Urmila, et al.
Publicado: (2022)

Cytomegalovirus infection in immunosuppressed patients after kidney transplantation
por: LUSCALOV, SIMONA, et al.
Publicado: (2016)

Rare oral lesions from cytomegalovirus in kidney transplant
por: Doraiswamy, Mohankumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n75k4jbemjaor4mh46rjr8equ1